RESUMO
Efforts to ban "gain-of-function" research on viruses and bacteria worry scientists.
Assuntos
Pesquisa Biomédica , Mutação com Ganho de Função , Wisconsin , Pesquisa Biomédica/economia , Pesquisa Biomédica/legislação & jurisprudência , Bactérias/genética , Bactérias/patogenicidade , Vírus/genética , Vírus/patogenicidade , Fungos/genética , Fungos/patogenicidadeRESUMO
In this Medical News article, JAMA Editor in Chief Kirsten Bibbins-Domingo, PhD, MD, MAS, and Alondra Nelson, PhD, the Harold F. Linder Professor at the Institute for Advanced Study, discuss effective AI regulation frameworks to accommodate innovation.
Assuntos
Inteligência Artificial , Pesquisa Biomédica , Política de Saúde , Invenções , Legislação Médica , Educação de Pós-Graduação em Medicina , Medicina , Inteligência Artificial/legislação & jurisprudência , Política de Saúde/legislação & jurisprudência , Invenções/legislação & jurisprudência , Pesquisa Biomédica/legislação & jurisprudênciaAssuntos
Pesquisa Biomédica , Governo Federal , Política , Apoio à Pesquisa como Assunto , Ciência , Argentina , Apoio à Pesquisa como Assunto/economia , Apoio à Pesquisa como Assunto/legislação & jurisprudência , Pesquisa Biomédica/economia , Pesquisa Biomédica/legislação & jurisprudência , Pesquisa Biomédica/tendências , Ciência/economia , Ciência/legislação & jurisprudência , Ciência/tendênciasRESUMO
La implementación de la Convención de Derechos de las Personas con Discapacidad obliga a los Estados Partes a realizar reformas legales que afectan a las normas que regulan la participación de las personas con discapacidad en la investigación biomédica clínica, en especial en los ensayos clínicos con medicamentos. En España, se ha tenido que reformar el Código Civil y la Ley General de Derechos de las Personas con Discapacidad para adecuar el ejercicio de la capacidad jurídica y para garantizar la accesibilidad cognitiva. Estas reformas podrían servir como modelo de las reformas que deben implementarse en otros países.(AU)
La implementació de la Convenció dels Drets de les Persones amb Discapacitat obliga als Estats Parts a realitzar reformes legals que afecten les normes que regulen la participació de les persones amb discapacitat en la investigació biomèdica clínica, especialment en els assaigs clínics amb medicaments. A Espanya, s'ha hagut de reformar el Codi Civil i la Llei General de Drets de les Persones amb Discapacitat per adequar l'exercici de la capacitat jurídica i garantir l'accessibilitat cognitiva. Aquestes reformes podrien servir com a model per a les reformes que han d'implementar-se en altres països.(AU)
The implementation of the Convention on the Rights of Persons with Disabilities obliges the States Parties to carry out legal reforms that affect the norms that regulate the participation of persons with disabilities in clinical biomedical research, especially in clinical trials with drugs. In Spain, the Civil Code and the General Act on the Rights of Persons with Disabilities have had to be reformed to adapt the exercise of legal capacity and to guarantee cognitive accessibility. These reforms could serve as a model for reforms to be implemented in other countries.(AU)
Assuntos
Humanos , Masculino , Feminino , Defesa das Pessoas com Deficiência , Pessoas com Deficiência , Pesquisa Biomédica/ética , Bioética , Direitos Civis , Pesquisa Biomédica/legislação & jurisprudência , EspanhaRESUMO
La realización de cualquier investigación con seres humanos o sus muestras biológicas requiere una valoración ética previa con el fin de evitar riesgos y problemas a todos los actores del proceso. La legislación al respecto es muy amplia, y hace hincapié en la preservación de los derechos de los pacientes en relación con los principios universales de autonomía, beneficencia y justicia. En este manuscrito se revisan las normativas sobre ensayos clínicos, estudios observacionales con medicamentos, proyectos de biobanco o cualquier otro tipo de estudio que se pueda realizar en el ámbito de la salud. Así mismo se analiza el papel de los comités de ética en investigación, la protección de datos y las bases de la integridad científica. (AU)
Any research conducted on human beings or human biological samples requires a prior ethical assessment to avoid risks and problems for all involved parties. The legislation in this regard is very broad and emphasizes the safeguarding of patient rights in relation to the universal principles of autonomy, beneficence and justice. The present article reviews the regulations applicable to clinical trials, observational studies with drugs, biobank projects or any other type of study that may be conducted in the health care field. It also addresses the role of research ethics committees, data protection and the foundations of scientific integrity. (AU)
Assuntos
Humanos , Ética em Pesquisa , Pesquisa/legislação & jurisprudência , Segurança Computacional , Comitês de Ética em Pesquisa , Espanha , Pesquisa Biomédica/legislação & jurisprudênciaAssuntos
Pesquisa Biomédica , COVID-19 , Coronavirus , Organização do Financiamento , National Institutes of Health (U.S.) , Humanos , Pesquisa Biomédica/economia , Pesquisa Biomédica/legislação & jurisprudência , Pesquisa Biomédica/tendências , COVID-19/epidemiologia , COVID-19/transmissão , COVID-19/virologia , National Institutes of Health (U.S.)/economia , National Institutes of Health (U.S.)/legislação & jurisprudência , Política , Estados Unidos , Zoonoses Virais/epidemiologia , Zoonoses Virais/transmissão , Zoonoses Virais/virologia , AnimaisRESUMO
Biden signs bill streamlining pot studies and production.
Assuntos
Pesquisa Biomédica , Cannabis , Pesquisa Biomédica/legislação & jurisprudência , Estados UnidosRESUMO
On October 6, 2022, President Biden announced that he is taking steps to pardon those convicted of simple marijuana possession at the federal level and reconsider the classification of cannabis as a Schedule I substance. At the same time, Congress is working to pass legislation to streamline research in the cannabis space. These efforts signal that federal marijuana laws that have been in place for the past 85 years have created a multitude of problems, including barriers to research, and the federal government is finally considering decisions to create change.
Assuntos
Cannabis , Governo Federal , Uso da Maconha , Uso da Maconha/legislação & jurisprudência , Pesquisa Biomédica/legislação & jurisprudênciaRESUMO
BACKGROUND: Nazi Germany surrendered to the Allies on May 8, 1945. Six months later, the Allies tried the surviving leaders of Nazi Germany at the first Nuremberg trial. Later, the United States conducted 12 additional trials. The first one, The Unites States of America versus Karl Brandt et al., has been dubbed the Doctors' Trial. During the trial, the prosecution relied on the testimony of Dr. Andrew Ivy and Dr. Leo Alexander. At the end of the trial, Judge Sebring enunciated 10 principles needed to conduct human subject research-the Nuremberg Code. Authorship of the Code has been the subject of dispute, with both Ivy and Alexander claiming sole authorship. METHODS: In the summer of 2017, I visited Duke University Medical Center's Archives and surveyed the contents of boxes labeled "Alexander's papers." I also explored online databases with information on the Doctors' Trial. Pertinent documents were compared across collections, and against scholarly works on the topic. RESULTS: Box 3 of Alexander's papers at Duke University Medical Center's Archives contains a three-page document with six principles that, nearly word for word, were included in what is known as the Nuremberg Code. Alexander's name and appointment are typed at the end of the document. CONCLUSIONS: Although the Nuremberg Code is likely to have been an unplanned collaboration among members of the prosecuting team and the judges, I present evidence suggesting that Alexander drafted the blueprint and was the main contributor to the final version of the Code.
Assuntos
Pesquisa Biomédica , Ética Médica , Ética em Pesquisa , Legislação Médica/história , Sujeitos da Pesquisa/legislação & jurisprudência , Pesquisa Biomédica/ética , Pesquisa Biomédica/legislação & jurisprudência , Alemanha , História do Século XX , Humanos , Socialismo Nacional/história , Médicos/história , Estados UnidosAssuntos
Anti-Inflamatórios/administração & dosagem , Pesquisa Biomédica/tendências , Colite Ulcerativa/tratamento farmacológico , Doença de Crohn/tratamento farmacológico , Desenvolvimento de Medicamentos/tendências , Imunossupressores/administração & dosagem , Pediatria/tendências , Adolescente , Fatores Etários , Anti-Inflamatórios/efeitos adversos , Pesquisa Biomédica/legislação & jurisprudência , Criança , Pré-Escolar , Ensaios Clínicos como Assunto , Colite Ulcerativa/diagnóstico , Colite Ulcerativa/epidemiologia , Colite Ulcerativa/imunologia , Doença de Crohn/diagnóstico , Doença de Crohn/epidemiologia , Doença de Crohn/imunologia , Difusão de Inovações , Aprovação de Drogas , Desenvolvimento de Medicamentos/legislação & jurisprudência , Cálculos da Dosagem de Medicamento , Feminino , Humanos , Imunossupressores/efeitos adversos , Masculino , Pediatria/legislação & jurisprudência , Projetos de Pesquisa/tendências , Fatores de TempoRESUMO
RESUMEN: La investigación científica en seres humanos es fundamental para el desarrollo y avance en la ciencia de la salud y para el bienestar de la sociedad. La necesidad de contar con principios éticos explícitos y un marco regulatorio, permitió en el año 2001 la aprobación de la Norma sobre Regulación de Ensayos Clínicos en Seres Humanos. La ley 20.120 (2006), norma la investigación científica en el ser humano, describe aspectos centrales para el desarrollo de la investigación, dando sustento legal a la creación de los Comités Éticos Científicos (CEC), entidades colegiadas que tienen por objeto velar por la protección de la vulneración de derechos y libertades de los participantes, pudiendo aprobar o rechazar los protocolos de los proyectos. En Chile al año 2021 se registran 62 CEC acreditados. La región Metropolitana concentra el 58,2 %, la zona Norte un 11,2 % y en el sur del país un 30,6 %, de ellos solo el 12,9 % están acreditados para evaluar ensayos clínicos aleatorizados (ECA). Los criterios éticos internacionales más utilizados son la Declaración de Helsinki, pautas éticas sobre la salud, bienestar y los derechos de los pacientes; El Consejo Internacional de Ciencias Médicas (CIOMS) que protege en entornos vulnerables de escasos recursos; y el Informe Belmont en la protección de los sujetos de investigación. Se concluye que las guías éticas nacionales e internacionales son pautas que guardan relación con la adecuada protección jurídica de los participantes, velando por el respeto a la autonomía, la justicia y la selección justa de los participantes, a través del consentimiento informado voluntario. El desarrollo de una cultura de conducta ética en la investigación se debe basar en tres dimensiones generales; el ambiente humano, ambiente político y mecanismos de la sociedad civil.
SUMMARY: Scientific research in human beings is essential for the development and advancement of health science and for the well-being of society. The need to have explicit ethical principles and a regulatory framework allowed in 2001 the approval of the Standard on the Regulation of Clinical Trials in Human Beings. Law 20,120 (2006), regulates scientific research in human beings and describes central aspects for the development of research, giving legal support to the creation of Scientific Ethics Committees (SEC), collegiate entities whose purpose is to ensure the protection of the vulnerability of rights and freedoms of the participants, being able to approve or reject the protocols of the projects. In Chile by 2021, 62 accredited CECs are registered. The Metropolitan region concentrates 58.2 %, the North zone 11.2 % and in the south of the country 30.6 %, of which only 12.9 % are accredited to evaluate randomized clinical trials (RCTs). The most widely used international ethical criteria are the Helsinki Declaration, ethical guidelines on health, well-being and the rights of patients; The International Council of Medical Sciences (CIOMS) that protects in vulnerability low-resource settings; and the Belmont Report on the protection of research subjects. It is concluded that the national and international ethical guidelines are appropriate legal ethical guidelines and risk-benefit ratio that protect the participants, ensuring respect for the autonomy, justice and fair selection of the participants, through voluntary informed consent. The development of a culture of ethical conduct in research must be based on three general dimensions; the human environment, political environment and mechanisms of civil society.
Assuntos
Humanos , Comitês de Ética em Pesquisa , Pesquisa Biomédica/legislação & jurisprudência , Acreditação , Projetos de Pesquisa , Chile , Ética em Pesquisa , Pesquisa Científica e Desenvolvimento TecnológicoRESUMO
BACKGROUND: The business of clinical research has changed in the past two decades, shifting from industrialised Western countries to so-called emerging markets such as Eastern Europe, Latin America and Africa. An appraisal of the trends could identify associated factors that may have implications for the local populations and their endemic diseases. OBJECTIVES: To identify potential reasons why emerging countries have become attractive places for international sponsors to conduct their clinical trials. METHODS: Using ClinicalTrials.gov, the Pan African Clinical Trials Registry, the National Health Research Database and the Nigeria Clinical Trials Registry, trend data on clinical research development were determined for two emerging African markets, Nigeria and South Africa (SA), from 2010 to 2018. Also, health data on the two countries from the fact sheets of health statistics of the World Health Organization were compared, as well as regulatory and ethical conditions. Available data were analysed using descriptive statistics and trend analysis. RESULTS: The impact of globalisation is evident from the upward trend in clinical trials in SA before 2010, and the clear downward trend thereafter. One reason for this change could be the alignment of SA's regulatory and ethical frameworks with the Western world. In contrast, the upward trend is only just beginning in Nigeria, with the introduction of ethical/regulatory frameworks, and supportive institutions making the business of clinical research more attractive on an international level. Although the number of international and local sponsors increased in Nigeria from 2010 to 2018, only the latter increased in SA, with the former decreasing over the same period. Overall, there is a mismatch between country-specific diseases and the drugs being tested, to the extent that leprosy, which is endemic in Nigeria, and tuberculosis in SA were not in the list of top 10 study areas in either country. CONCLUSIONS: The globalisation trend is evident in the clinical trials business, but cannot be generalised to all emerging countries. Timing and intensity vary from country to country relative to factors that advance the existing profit-orientated business models of the sponsors. Furthermore, various diseases have been localised, which entails a diversely increasing need for research.